Four of the eight patients who received SENTI-202 manufactured entirely from non-Donor X NK cells achieved a composite complete remission — exactly one. That 12.5% cCR rate, set against 50% in the Donor X cohort, is the number that reshapes everything about how this program moves forward, and it explains why FDA alignment on a registrational path was achievable at all.
The Phase 1 dataset covering all 22 patients carries a 44% ORR and 37.5% cCR at the recommended Phase 2 dose, with every complete remission confirmed MRD-negative. Those are already competitive numbers in relapsed/refractory AML, a setting where approved agents rarely produce deep responses and almost never sustain them. The durability data sharpens the picture further: all CR and CRh responders who were in remission at the ASH 2025 data cut remain in remission seven months later, with the longest response now exceeding 21 months. In a disease where median survival after second relapse is measured in weeks, that duration is not incremental — it is categorical.
The Donor X finding is both the program’s biggest asset and its most consequential operational constraint. The phenotype appears in roughly half of adult donors, is independent of HLA or KIR matching, and retrospective preclinical data in the MV4-11 NSG model confirm the survival advantage is reproducible. Standardizing manufacturing around Donor X material is the correct call, but it immediately raises the question of supply chain depth at pivotal scale. A single-arm multi-center trial intended to support registration will demand consistent, high-volume batches from a screened donor pool — and any manufacturing variability that slips through will land directly on the efficacy readout with no control arm to absorb it. CMC execution, not clinical enrollment, is now the rate-limiting variable for this program.
The single endpoint to watch is whether MRD-negative cCR rates in the registrational cohort — manufactured exclusively from Donor X material — hold at or above the 50% signal seen in the Phase 1 subgroup. If they do, Senti Bio has a realistic accelerated approval case. If the rate regresses toward the pooled 37.5%, the conversation with FDA about sufficiency gets harder regardless of durability.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
